Metastatic breast cancer is diagnosed through a combination of imaging scans, biopsies of suspected metastatic sites, and molecular testing of the cancer’s biology. A diagnosis is confirmed when breast cancer cells are found in organs beyond the breast and nearby lymph nodes, most commonly the bones, lungs, liver, or brain. The process typically involves multiple steps because doctors need to both confirm the spread and understand the tumor’s current biology to choose the right treatment.
What Makes Breast Cancer “Metastatic”
Breast cancer becomes stage IV when it has spread to distant organs. In staging terms, this is defined by an M1 classification, meaning cancer has been confirmed in a distant site either through imaging, physical exam, or a biopsy showing cancer deposits larger than 0.2 mm. Some people are diagnosed with metastatic disease from the start, while others develop it months or years after treatment for earlier-stage breast cancer.
The distinction matters because metastatic breast cancer is treated as a systemic disease rather than a localized one. The diagnostic workup reflects this: it’s designed not just to find where the cancer has gone, but to characterize the tumor so treatment can be precisely matched to its molecular profile.
Imaging Scans Used to Find Metastases
The standard imaging workup includes a CT scan of the chest with contrast, a CT scan of the abdomen and pelvis, and a nuclear medicine bone scan. These are the most widely used tools because they’re available at virtually every cancer center, covered by insurance, and accepted as standard across clinical trials in the U.S. and internationally.
PET/CT scans are not technically considered standard imaging, but they’re widely used because a single scan can assess organ involvement, lymph nodes, and bones all at once. For detecting bone metastases specifically, PET/CT has a sensitivity of 88% to 100% and specificity of 84% to 99%, compared with 81% to 98% sensitivity and 71% to 100% specificity for traditional bone scans. Those differences can be clinically meaningful, sometimes changing treatment decisions.
MRI fills a specific gap. PET scans and CT scans of the head aren’t sensitive enough to detect small brain metastases. A brain MRI with contrast is the required tool for evaluating suspected spread to the central nervous system. MRI of the spine is also the best option when doctors need to check for spinal cord compression or cancer spreading to the membranes surrounding the brain and spinal cord.
Why a New Biopsy Matters
One of the most important parts of diagnosing metastatic breast cancer is taking a biopsy of the metastatic site itself, not just relying on information from the original tumor. This step is critical because cancer can change its characteristics as it spreads.
A large meta-analysis published in the Journal of the National Cancer Institute found that receptor status shifts between the primary tumor and metastatic sites are surprisingly common. About 19% of cases showed a change in estrogen receptor status, 31% showed a change in progesterone receptor status, and 10% showed a change in HER2 status. Progesterone receptor changes were especially dramatic: nearly half of tumors that were originally progesterone receptor-positive converted to negative by the time they metastasized.
These shifts directly affect treatment. A tumor that was HER2-negative in the breast but HER2-positive in a liver metastasis, for example, would qualify for targeted therapies it wouldn’t have been eligible for based on the original biopsy alone. European guidelines recommend that when receptor status differs between the primary tumor and the metastatic site, treatment should be guided by the metastatic biopsy results.
Genomic and Biomarker Testing
Beyond the standard receptor tests for estrogen, progesterone, and HER2, metastatic breast cancer increasingly requires genomic testing to identify specific mutations that open the door to targeted therapies. This is especially true for hormone receptor-positive, HER2-negative cancers, where several new drugs are matched to specific genetic alterations.
The key mutations doctors look for include changes in genes involved in tumor growth signaling and hormone resistance. About 33% to 43% of hormone receptor-positive metastatic breast cancers carry a mutation in a gene called PIK3CA, making it the most common actionable target. Mutations linked to hormone therapy resistance appear in roughly 8% of patients at first-line treatment but climb to 33% to 39% by the time patients reach third-line therapy, reflecting how cancers evolve under treatment pressure. Other relevant mutations occur in about 5% to 7% of cases each.
Current recommendations call for serial genomic testing using liquid biopsy (a blood draw that detects tumor DNA circulating in the bloodstream), with a follow-up tissue biopsy if no actionable mutations are found in the blood. This approach recognizes that the tumor’s genetic landscape shifts over time, particularly as it’s exposed to different treatments.
Liquid Biopsies in Practice
Liquid biopsies analyze fragments of tumor DNA shed into the bloodstream, known as circulating tumor DNA. They offer a less invasive alternative to tissue biopsies and can be repeated over time to track how the cancer is evolving. For metastatic breast cancer, liquid biopsies are now used clinically to detect specific mutations that guide treatment choices.
Recent clinical trial data show the practical value of this approach. In the SERENA-6 trial, detecting a specific resistance mutation through a blood-based test during routine monitoring allowed doctors to switch therapy before the cancer showed visible growth on scans. Patients who switched early based on this blood test had a median progression-free survival of 16 months, compared with 9.2 months for those who continued their existing treatment. This represents a shift toward using molecular signals, not just imaging, to guide decisions in real time.
Blood Tumor Markers and Their Limits
Blood tests for tumor markers like CA 15-3 and CEA are sometimes part of the diagnostic picture, but they have significant limitations. CA 15-3 has low overall sensitivity and specificity for breast cancer. Levels can be elevated in healthy people, in benign conditions like liver disease, and in other cancers entirely. Normal levels don’t rule out metastatic disease, and elevated levels don’t confirm it.
These markers are most commonly used to monitor response during treatment rather than to make an initial diagnosis. Even in that role, they should never be interpreted alone. CA 15-3 levels can spike falsely in the first four to six weeks of a new therapy, which can be alarming but doesn’t necessarily mean the cancer is growing. No randomized clinical trial has shown that tracking these markers after primary treatment improves survival or quality of life, so their use in surveillance remains controversial.
What the Full Diagnostic Picture Looks Like
Putting it all together, diagnosing metastatic breast cancer is a layered process. It typically starts with imaging that reveals suspicious findings in distant organs. A biopsy of the metastatic site confirms the cancer’s origin and provides fresh receptor status. Genomic testing, often through a blood draw, identifies mutations that match available targeted therapies. Standard blood markers may be checked as a baseline for monitoring but play no reliable role in confirming the diagnosis itself.
The entire workup can take a few weeks from the first suspicious scan to complete molecular profiling. The timeline depends partly on where the metastasis is located (a bone biopsy may require different coordination than a liver biopsy) and partly on how quickly genomic results come back, which typically takes one to three weeks for liquid biopsy panels. The wait can feel agonizing, but each piece of information shapes the treatment plan in ways that meaningfully affect outcomes.